(Q36720915)

15 August 2017

1 reference

title

ABCB1 pharmacogenetics: progress, pitfalls, and promise (English)

1 reference

15 August 2017

Chinn LW

1

1 reference

15 August 2017

Kroetz DL

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Clinical Pharmacology & Therapeutics

15 August 2017

1 reference

15 August 2017

81

1 reference

15 August 2017

265-269

1 reference

15 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100052

15 August 2017

0 references

cites work

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Identification of functionally variant MDR1 alleles among European Americans and African Americans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Overview of the pharmacogenetics of HIV therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Potential role of drug transporters in the pathogenesis of medically intractable epilepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Limited P-glycoprotein mediated efflux for anti-epileptic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Effect of MDR1 haplotype on risk of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Analysis of MDR1 haplotypes in Parkinson's disease in a white population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Glucocorticoid resistance in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100052

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100052

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference